Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Everhart Financial Group Inc.

Everhart Financial Group Inc. raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,046 shares of the medical equipment provider’s stock after purchasing an additional 368 shares during the period. Everhart Financial Group Inc.’s holdings in Intuitive Surgical were worth $1,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Creekmur Asset Management LLC raised its holdings in shares of Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. Ridgewood Investments LLC purchased a new position in Intuitive Surgical during the second quarter worth about $26,000. Delos Wealth Advisors LLC raised its holdings in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Godsey & Gibb Inc. raised its holdings in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares in the last quarter. Finally, LRI Investments LLC purchased a new position in Intuitive Surgical during the first quarter worth about $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 0.1 %

Shares of ISRG opened at $535.75 on Tuesday. The firm has a market cap of $190.82 billion, a PE ratio of 86.13, a price-to-earnings-growth ratio of 5.27 and a beta of 1.39. The company’s fifty day moving average is $493.92 and its two-hundred day moving average is $452.79. Intuitive Surgical, Inc. has a fifty-two week low of $281.12 and a fifty-two week high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Mizuho increased their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Citigroup increased their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. Wells Fargo & Company increased their target price on shares of Intuitive Surgical from $466.00 to $549.00 and gave the company an “overweight” rating in a report on Friday, October 18th. Finally, Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 396 shares of Intuitive Surgical stock in a transaction on Monday, August 26th. The shares were sold at an average price of $486.88, for a total transaction of $192,804.48. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,680,761.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 396 shares of Intuitive Surgical stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $486.88, for a total transaction of $192,804.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,680,761.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,006 shares of company stock valued at $33,727,766 in the last quarter. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.